Anavex Life Sciences (AVXL) Operating Expenses (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of Operating Expenses data on file, last reported at $6.8 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 50.1% year-over-year to $6.8 million; the trailing twelve-month figure through Dec 2025 stood at $44.6 million (down 19.05% YoY), and the FY2025 full-year result was $51.4 million, down 2.78% from the prior year.
• Operating Expenses eased to $6.8 million in Q4 2025, from $10.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $15.4 million in Q4 2022 to a low of $6.8 million in Q4 2025.
• A 5-year average of $12.5 million and a median of $12.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 122.41% in 2021 and plunged 50.1% in 2025, its largest moves.
• Tracing AVXL's Operating Expenses over 5 years: stood at $11.7 million in 2021, then surged by 31.22% to $15.4 million in 2022, then declined by 26.04% to $11.4 million in 2023, then increased by 19.46% to $13.6 million in 2024, then sank by 50.1% to $6.8 million in 2025.
• Business Quant data shows AVXL's Operating Expenses at $6.8 million in Q4 2025, $10.8 million in Q3 2025, and $14.5 million in Q2 2025.